Equities

Claritas Pharmaceuticals Inc

CLAS.H:NEX

Claritas Pharmaceuticals Inc

Actions
  • Price (CAD)0.025
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jul 21 2022.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2020202020192018
ASSETS
Cash And Short Term Investments0.010.030.23
Total Receivables, Net0.210.120.52
Total Inventory------
Prepaid expenses0.76----
Other current assets, total------
Total current assets0.980.150.75
Property, plant & equipment, net------
Goodwill, net1.774.699.47
Intangibles, net7.692049
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets102560
LIABILITIES
Accounts payable0.911.561.66
Accrued expenses0.320.30--
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.930.360.25
Other current liabilities, total4.983.54--
Total current liabilities7.135.767.82
Total long term debt02.380
Total debt0.932.740.25
Deferred income tax1.776.6511
Minority interest------
Other liabilities, total0.041431
Total liabilities8.942950
SHAREHOLDERS EQUITY
Common stock----44
Additional paid-in capital57563.92
Retained earnings (accumulated deficit)(55)(59)(38)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1.51(3.44)9.76
Total liabilities & shareholders' equity102560
Total common shares outstanding272613
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.